Responsibilities:

The department currently has 1 chief physician, 1 associate chief physician, 5 attending physicians, 1 doctor and 6 masters. It has accumulated extensive clinical experience in the diagnosis and treatment of various anemia, hemolytic diseases, immune cytopenias, bleeding and coagulation diseases, various types of leukemia, lymphoma, multiple myeloma, aplastic anemia, as well as various clinical hematological concurrent diseases such as DIC, agranulocytosis and thrombosis. At present, it is conducting a clinical study of new CAR-T cells in the treatment of relapsed/refractory B cell tumors. Over the years, it has diagnosed and treated a large number of patients with solid tumors such as colon cancer, gastric cancer, breast cancer, lung cancer, and esophageal cancer, and established standardized laboratory examination methods and clinical treatment options, which have achieved good efficacy and improved the response rate and disease-free survival rate of patients.

Academic status:

It has long been cooperating with many first-class hematology and oncology specialties and laboratories in China, and has carried out a number of scientific research work in combination with clinical practice, including the in-depth study on the etiology and pathogenesis of malignant tumors, early warning and early diagnosis of malignant tumors, individualized comprehensive treatment of tumors, research and development of anti-tumor drugs, cancer biotherapy, etc.; it has undertaken several provincial and municipal programs, such as drug resistance research of leukemia and multiple myeloma, treatment of refractory ITP, and research on lung cancer drug resistance genes, enabling the diagnosis and treatment of hematological diseases and tumors to be in line with domestic and international standards, and it has published several articles in SCI, national and provincial journals.